💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for PELI

No earnings history available for this symbol.

📰 Related News & Research

• Sichuan Biokin Pharmaceutical (688506) Hong Kong IPO: Innovative Oncology Pipeline, Global Strategy & Key Risk Factors Explained
  February 14, 2026
  

  Baili Pharmaceutical IPO Analysis: Growth, Strategy & Outlook for Investors Company Name: Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical IPO:…

• Ever Glory United Holdings (EGUH) 2026 Outlook: Doubling Profits, S$4bn Tender Pipeline, and High Dividend Growth 124
  February 5, 2026
  

  Broker Name: CGS International Date of Report: February 4, 2026 Excerpt from CGS International report. Report Summary Ever Glory United Holdings (EGUH) is set to…

• Capland Ascott FY25 Results: Stable DPU, AEI Pipeline to Drive Future Growth – Investment Outlook & Key Metrics 123
  February 4, 2026
  

  Broker Name: DBS Date of Report: (Date not explicitly stated in document; inferred as FY25 results, likely published in mid-2024.) Excerpt from DBS report. Report…

• Eikon Therapeutics IPO: Pipeline, Technology Platform, Key Collaborations & Investment Highlights for 2026
  January 31, 2026
  

  Eikon Therapeutics, Inc. IPO Analysis: In-Depth Investor Guide Eikon Therapeutics, Inc. Date of prospectus: January 28, 2026 Eikon Therapeutics IPO: A Deep Dive Into a…

• AgomAb Therapeutics NV IPO: Pipeline, Financials, Risks & Opportunities Explained
  January 31, 2026
  

  AgomAb Therapeutics NV IPO: In-Depth Investor Analysis, Risks, Financials, and Growth Outlook AgomAb Therapeutics NV Date of Prospectus: 2026 AgomAb Therapeutics NV IPO: Growth-Driven Biotech…

• Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Pipeline, Growth Strategies & Global Expansion (2025 Prospectus Highlights)
  January 17, 2026
  

  Baili Pharmaceutical: Hong Kong IPO Analysis, Offer Details, Financials & Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical’s Hong Kong…

• Soilbuild Construction Group Targets S$1bn Order Book by End-2026 With Strong Pipeline and Higher Dividend Potential 1
  January 16, 2026
  

  Broker: CGS InternationalDate of Report: January 15, 2026 Excerpt from CGS International report. Report Summary Soilbuild Construction Group (SBCG) maintains a strong S\$1bn tender book…

• Suzhou Ribo Life Science IPO: Leading the Future of siRNA Oligonucleotide Therapeutics – Company Overview, Pipeline, and Competitive Edge 1116272278
  January 4, 2026
  

  Suzhou Ribo Life Science Co., Ltd. IPO: Investor Analysis & Outlook Suzhou Ribo Life Science Co., Ltd. Date of prospectus: December 31, 2025 Suzhou Ribo…

• Hanx Biotech IPO Prospectus 2025: Innovative Cancer & Autoimmune Drug Pipeline, Key Products HX009, HX301, HX044, Investment Highlights & Market Opportunities
  December 20, 2025
  

  Hanx Biopharmaceuticals (Wuhan) Co., Ltd. IPO Analysis – December 15, 2025 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Date of prospectus: December 15, 2025 Hanx Biopharmaceuticals Pre-Revenue…

• Innovative PDGF Drug Developer Huarenshengwu: Pipeline, Market Strategy, and IPO Prospectus Overview
  December 20, 2025
  

  B&K Corporation Limited IPO: In-Depth Analysis for Investors B&K Corporation Limited Date of Prospectus: December 12, 2025 B&K Corporation Limited’s Landmark Hong Kong IPO: Deep…

🔍 View more Reports